Stempeutics gets DCGI nod for phase-III clinical trial on its product for treating COVID patients
The company will be using its stem cell product, Stempeucel, for conducting the label extension phase-III clinical trial
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Stempeucel
Stempeutics’ allogeneic cell therapy gets DCGI approval, Cipla to market and distribute…
Indicated for the treatment of CLI due to Buerger’s Disease and Atherosclerotic Peripheral Arterial Disease, it is the first…
We are in touch with CDSCO, will submit clinical trial protocol for approval of COVID-19 treatment
Stempeutics plans to conduct clinical research in Europe and has partnered with a global consortium of cell therapy companies to…
US patent office issued notification to grant patent to Stempeutics for its stem cell drug…
Stempeucel is derived from allogeneic pooled mesenchymal stromal cells extracted from the bone marrow of healthy, adult voluntary…
DCGI gives limited approval to market Stempeutics’ allogeneic cell therapy
Stempeucel is used in the treatment of Buerger’s disease
Stempeutics receives Japan process patent for its stem cell drug ‘Stempeucel’
Stempeucel is derived from allogeneic pooled mesenchymal stromal cells extracted from the bone marrow of healthy, adult voluntary…